Scientist, Process Chemistry at ORIC Pharmaceuticals
South San Francisco, CA, US

We are seeking a highly motivated process research and development chemist with a proven record of sustained laboratory achievement and innovation to join our growing CMC group at ORIC Pharmaceuticals. The successful candidate will report to the Director of Process Chemistry.


  • Conducting laboratory scale experiments to identify routes and to optimize reaction conditions.
  • Collecting and interpretating the necessary data (HPLC, XRPD, PLM, NMR) to reach conclusions from experiments.
  • Independently propose, design, and carry out reactions with control of relevant experimental factors (temperature, time, stir rate, water content) based on mechanistic understanding to address problems and gain further understanding of chemistry.
  • Function as a subject matter expert for transfer/development of synthetic chemistry processes to external vendors and CMOs.
  • Familiarity with regulatory guidance and operating in cGMP environment.
  • Prepare presentation materials and clearly communicate research results to manager, and at internal and external meetings.

Qualifications & Experience:

  • Masters in organic chemistry with >7 years of relevant pharmaceutical/Biotech industry experience, or PhD in organic chemistry with 0-2 years of relevant pharmaceutical/Biotech industry experience.
  • Experienced with routine laboratory techniques such as reaction set-up, crystallization, and handling hazardous/toxic materials.
  • Familiarity with analytical tools used in process development (HPLC, NMR, KF, PLM, XRPD).
  • Experience with reaction optimization, statistical reaction modeling, and process characterization.
  • Understanding of reaction safety hazards assessment and its application to reaction scale-up.

About ORIC Pharmaceuticals:
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer.  ORIC’s lead product candidate, ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors.  ORIC-101 is currently in two separate Phase 1b trials of ORIC-101 in combination with (1) Xtandi (enzalutamide) in metastatic prostate cancer and (2) Abraxane (nab-paclitaxel) in advanced or metastatic solid tumors. ORIC’s other product candidates include (1) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, and (2) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the embryonic ectoderm development (EED) subunit being developed for prostate cancer.  Beyond these three product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms.  ORIC has offices in South San Francisco and San Diego, California.  For more information, please go to